SAI - Detailed view

HBVAXPRO Inj Susp 40 µg 1 Stk

Drug

Name

HBVAXPRO 40, Injektionssuspension

Field of application

aktive Immunisierung gegen Hepatitis B, bei Dialyse- und Prädialysepatienten, ab dem vollendeten 19. Lebensjahr

ATC

J07BC01 - HEPATITIS B, PURIFIED ANTIGEN

08.08. – vaccines

Use

HAM – Human medicine

pharmaceutical form

SUPA – Parenteral suspension

Remedy code

I – vaccines

Dispensing categories

B – Dispensed on prescription by a physician or veterinarian (B)

Authorisation status

Z – approved

Authorisation number

00545

Initial registration date

4/18/1988

Expiry date

12/31/9999

Dosage strength

Name

HBVAXPRO 40, Injektionssuspension

Field of application

aktive Immunisierung gegen Hepatitis B, bei Dialyse- und Prädialysepatienten, ab dem vollendeten 19. Lebensjahr

Dosage strength number

Authorisation status

Z – approved

Package

GTIN**

7680005450012

Trade status*

In trade from / since 4/18/1988

Status

A/R – Authorised / referenced

Package size

1 vial(s)

Application type

IMU – Intramuscular use

Package code

001

Authorisation status

Z – approved

Declaration

Component

Active substance

40 µg hepatitidis B viri antigenum ADNr

Excipient

0.5 mg aluminium
aluminii hydroxyphosphas sulfas amorphus
borax
natrii chloridum
aqua ad iniectabile
3.5 mg natrium

Spezialitätenliste***

Status

Date of deletion

Compulsory until

Public price (CHF)

62.20

Limitation points

None

Limitation

Yes

SB Deductible

10%

Generic

Authorisation holder

GLN**

7601001001138

Address

MSD Merck Sharp & Dohme AG
Werftestrasse 4
6005 Luzern (LU)

Date of revision of the text

9/17/2025

Information for prof.

Leaflet

Report error

Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.